Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Rheumatol ; 30(7): 1479-84, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12858444

RESUMO

OBJECTIVE: Hyperhomocysteinemia adversely affects the endothelium, although the exact mechanism is unclear. Systemic lupus erythematosus (SLE) is an inflammatory disease with a high atherothrombotic tendency. We examined whether acute hyperhomocysteinemia exacerbates endothelial and platelet dysfunction in patients with SLE. METHODS: Twelve SLE patients and 15 controls were recruited. Oral methionine was used to achieve acute hyperhomocysteinemia. Endothelial function was assessed by flow-mediated dilatation (FMD) of the brachial artery; also assessed were the levels of von Willebrand factor (vWF) and plasminogen activator inhibitor type 1 (PAI-1). Platelet activation was assessed by the levels of beta-thromboglobulin (beta-TG), fibrinogen binding, and P-selectin expression using flow cytometry. RESULTS: After oral methionine loading, vWF levels increased significantly, whereas FMD remained unchanged in both groups. PAI-1 increased significantly only in controls. Fibrinogen binding to platelets increased significantly only in SLE patients. Beta-TG remained unchanged in SLE patients but increased significantly in controls. Platelet P-selectin expression did not change in either group. CONCLUSION: These results suggest that the prothrombotic tendency after acute hyperhomocysteinemia is mediated by endothelial dysfunction and platelet activation in patients with SLE and healthy controls.


Assuntos
Endotélio Vascular/fisiopatologia , Hiper-Homocisteinemia/fisiopatologia , Lúpus Eritematoso Sistêmico/fisiopatologia , Ativação Plaquetária , Vasodilatação , Doença Aguda , Administração Oral , Adulto , Artéria Braquial/efeitos dos fármacos , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Feminino , Citometria de Fluxo , Humanos , Hiper-Homocisteinemia/sangue , Lúpus Eritematoso Sistêmico/sangue , Masculino , Metionina/administração & dosagem , Metionina/farmacologia , Inibidor 1 de Ativador de Plasminogênio/sangue , Fluxo Sanguíneo Regional/efeitos dos fármacos , Fluxo Sanguíneo Regional/fisiologia , Vasodilatação/efeitos dos fármacos , Fator de von Willebrand/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA